The companies said they intend to increase their salesforce by 30% as they aim for 100,000 patients by 2026. For the moment, Leqembi is the only Alzheimer’s drug on the market designed to slow the course of the disease. A decision on Lilly’s donanemab has been delayed until the FDA convenes an advisory panel.
Source – ETHealth World
